The company scaled up manufacturing process for Laccure Pessary product. A search has been started for a company interested in acquiring Laccure and launching the product.
Laccure CEO Jeanette Robertsson said: "We are proud to announce that the final development stage, the up-scaling of the manufacturing process, for Laccure® Pessary, our new, antibiotic-free, non-prescription product for the treatment and prevention of bacterial vaginosis, is now completed.
"The product is thus ready for launch. Our objective from the start of the project has been to sell Laccure to an established company that will take the product to market."
Laccure stated BV is the most common vaginal infection in women of childbearing age and it is estimated that over 300 million women are infected per year globally.
The company’s product is based on a substance that releases lactic acid over several days to lower the elevated vaginal pH.
It needs to be administered once to treat a BV infection, and once a month as prevention for women with frequent recurrences.